MEDRx is the world's first pharmaceutical company capitalizing on ionic liquid technology to develop novel / unique transdermal medicines.

Our core technology, ILTS®, allows compounds with weak absorbability and/or low solubility to be available as transdermal preparations by means of increasing their solubility and absorbability dramatically.

Through capitalizing on our inventive transdermal drug delivery technology, it is possible to create novel value-added medicines (maximized beneficial effects and lower side effects).

Thanks to our proven technologies, since February 2013, MEDRx has been successfully listed on the Mothers (market of the high-growth and emerging stocks) of the Tokyo Stock Exchange.